Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: A pilot study

Ali Hallal, Stephen M. Cohn, Nicholas Namias, Fahim Habib, Gio Baracco, Ronald J. Manning, Bruce Crookes, Carl I. Schulman

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy and safety of inhaled tobramycin (TOBI) in the treatment of ventilator-associated pneumonia (VAP) in a randomized, double-blind pilot study. Patients and Methods: Ten patients from a cohort of 108 mechanically ventilated patients with documented clinical and bacteriological evidence of VAP caused by Pseudomonas aeruginosa or Acinetobacter spp. in the surgical and trauma intensive care units of a university teaching hospital were randomized to receive either TOBI (n = 5) or intravenous tobramycin (TOBRA; n = 5). The two groups were similar in their Acute Physiology and Chronic Health Evaluation (APACHE) score, Clinical Pulmonary Infection Score (CPIS), and Multiple Organ Dysfunction Score (MODS) prior to randomization. The primary outcome measure was resolution of pneumonia. The CPIS and MODS were used as objective indicators of clinical progress. Results: All TOBI patients had clinical resolution of VAP. Two TOBRA patients were considered failures. One had deterioration in MODS, and the other had doubling of his serum creatinine concentration. The patients treated with TOBI may have had more ventilator-free days than those receiving TOBRA, but the difference was not statistically significant owing to the small sample size (24 ± 3 vs. 14 ± 13 days; p = 0.12). Conclusion: Aerosolized tobramycin for the treatment of VAP appeared safe and effective in this pilot study. A larger study is warranted to determine if aerosolized tobramycin will lead to better outcomes than intravenous tobramycin when used for the treatment of VAP.

Original languageEnglish (US)
Pages (from-to)73-81
Number of pages9
JournalSurgical Infections
Volume8
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Ventilator-Associated Pneumonia
Tobramycin
Organ Dysfunction Scores
Therapeutics
Lung
Acinetobacter
APACHE
Mechanical Ventilators
Critical Care
Random Allocation
Infection
Double-Blind Method
Teaching Hospitals
Sample Size
Pseudomonas aeruginosa
Intensive Care Units
Creatinine
Pneumonia
Outcome Assessment (Health Care)
Safety

ASJC Scopus subject areas

  • Surgery
  • Microbiology (medical)

Cite this

Hallal, A., Cohn, S. M., Namias, N., Habib, F., Baracco, G., Manning, R. J., ... Schulman, C. I. (2007). Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: A pilot study. Surgical Infections, 8(1), 73-81. https://doi.org/10.1089/sur.2006.051

Aerosolized tobramycin in the treatment of ventilator-associated pneumonia : A pilot study. / Hallal, Ali; Cohn, Stephen M.; Namias, Nicholas; Habib, Fahim; Baracco, Gio; Manning, Ronald J.; Crookes, Bruce; Schulman, Carl I.

In: Surgical Infections, Vol. 8, No. 1, 02.2007, p. 73-81.

Research output: Contribution to journalArticle

Hallal, A, Cohn, SM, Namias, N, Habib, F, Baracco, G, Manning, RJ, Crookes, B & Schulman, CI 2007, 'Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: A pilot study', Surgical Infections, vol. 8, no. 1, pp. 73-81. https://doi.org/10.1089/sur.2006.051
Hallal, Ali ; Cohn, Stephen M. ; Namias, Nicholas ; Habib, Fahim ; Baracco, Gio ; Manning, Ronald J. ; Crookes, Bruce ; Schulman, Carl I. / Aerosolized tobramycin in the treatment of ventilator-associated pneumonia : A pilot study. In: Surgical Infections. 2007 ; Vol. 8, No. 1. pp. 73-81.
@article{fd58e08ffc3b455b905d4f4a307389da,
title = "Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: A pilot study",
abstract = "Objective: To evaluate the efficacy and safety of inhaled tobramycin (TOBI) in the treatment of ventilator-associated pneumonia (VAP) in a randomized, double-blind pilot study. Patients and Methods: Ten patients from a cohort of 108 mechanically ventilated patients with documented clinical and bacteriological evidence of VAP caused by Pseudomonas aeruginosa or Acinetobacter spp. in the surgical and trauma intensive care units of a university teaching hospital were randomized to receive either TOBI (n = 5) or intravenous tobramycin (TOBRA; n = 5). The two groups were similar in their Acute Physiology and Chronic Health Evaluation (APACHE) score, Clinical Pulmonary Infection Score (CPIS), and Multiple Organ Dysfunction Score (MODS) prior to randomization. The primary outcome measure was resolution of pneumonia. The CPIS and MODS were used as objective indicators of clinical progress. Results: All TOBI patients had clinical resolution of VAP. Two TOBRA patients were considered failures. One had deterioration in MODS, and the other had doubling of his serum creatinine concentration. The patients treated with TOBI may have had more ventilator-free days than those receiving TOBRA, but the difference was not statistically significant owing to the small sample size (24 ± 3 vs. 14 ± 13 days; p = 0.12). Conclusion: Aerosolized tobramycin for the treatment of VAP appeared safe and effective in this pilot study. A larger study is warranted to determine if aerosolized tobramycin will lead to better outcomes than intravenous tobramycin when used for the treatment of VAP.",
author = "Ali Hallal and Cohn, {Stephen M.} and Nicholas Namias and Fahim Habib and Gio Baracco and Manning, {Ronald J.} and Bruce Crookes and Schulman, {Carl I.}",
year = "2007",
month = "2",
doi = "10.1089/sur.2006.051",
language = "English (US)",
volume = "8",
pages = "73--81",
journal = "Surgical Infections",
issn = "1096-2964",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Aerosolized tobramycin in the treatment of ventilator-associated pneumonia

T2 - A pilot study

AU - Hallal, Ali

AU - Cohn, Stephen M.

AU - Namias, Nicholas

AU - Habib, Fahim

AU - Baracco, Gio

AU - Manning, Ronald J.

AU - Crookes, Bruce

AU - Schulman, Carl I.

PY - 2007/2

Y1 - 2007/2

N2 - Objective: To evaluate the efficacy and safety of inhaled tobramycin (TOBI) in the treatment of ventilator-associated pneumonia (VAP) in a randomized, double-blind pilot study. Patients and Methods: Ten patients from a cohort of 108 mechanically ventilated patients with documented clinical and bacteriological evidence of VAP caused by Pseudomonas aeruginosa or Acinetobacter spp. in the surgical and trauma intensive care units of a university teaching hospital were randomized to receive either TOBI (n = 5) or intravenous tobramycin (TOBRA; n = 5). The two groups were similar in their Acute Physiology and Chronic Health Evaluation (APACHE) score, Clinical Pulmonary Infection Score (CPIS), and Multiple Organ Dysfunction Score (MODS) prior to randomization. The primary outcome measure was resolution of pneumonia. The CPIS and MODS were used as objective indicators of clinical progress. Results: All TOBI patients had clinical resolution of VAP. Two TOBRA patients were considered failures. One had deterioration in MODS, and the other had doubling of his serum creatinine concentration. The patients treated with TOBI may have had more ventilator-free days than those receiving TOBRA, but the difference was not statistically significant owing to the small sample size (24 ± 3 vs. 14 ± 13 days; p = 0.12). Conclusion: Aerosolized tobramycin for the treatment of VAP appeared safe and effective in this pilot study. A larger study is warranted to determine if aerosolized tobramycin will lead to better outcomes than intravenous tobramycin when used for the treatment of VAP.

AB - Objective: To evaluate the efficacy and safety of inhaled tobramycin (TOBI) in the treatment of ventilator-associated pneumonia (VAP) in a randomized, double-blind pilot study. Patients and Methods: Ten patients from a cohort of 108 mechanically ventilated patients with documented clinical and bacteriological evidence of VAP caused by Pseudomonas aeruginosa or Acinetobacter spp. in the surgical and trauma intensive care units of a university teaching hospital were randomized to receive either TOBI (n = 5) or intravenous tobramycin (TOBRA; n = 5). The two groups were similar in their Acute Physiology and Chronic Health Evaluation (APACHE) score, Clinical Pulmonary Infection Score (CPIS), and Multiple Organ Dysfunction Score (MODS) prior to randomization. The primary outcome measure was resolution of pneumonia. The CPIS and MODS were used as objective indicators of clinical progress. Results: All TOBI patients had clinical resolution of VAP. Two TOBRA patients were considered failures. One had deterioration in MODS, and the other had doubling of his serum creatinine concentration. The patients treated with TOBI may have had more ventilator-free days than those receiving TOBRA, but the difference was not statistically significant owing to the small sample size (24 ± 3 vs. 14 ± 13 days; p = 0.12). Conclusion: Aerosolized tobramycin for the treatment of VAP appeared safe and effective in this pilot study. A larger study is warranted to determine if aerosolized tobramycin will lead to better outcomes than intravenous tobramycin when used for the treatment of VAP.

UR - http://www.scopus.com/inward/record.url?scp=34247129544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247129544&partnerID=8YFLogxK

U2 - 10.1089/sur.2006.051

DO - 10.1089/sur.2006.051

M3 - Article

C2 - 17381399

AN - SCOPUS:34247129544

VL - 8

SP - 73

EP - 81

JO - Surgical Infections

JF - Surgical Infections

SN - 1096-2964

IS - 1

ER -